Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 4/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.34 |
| ▸ | MMP2 | P08253 | 4/20 | 0.34 |
| ▸ | MMP3 | P08254 | 4/20 | 0.34 |
| ▸ | MMP12 | P39900 | 4/20 | 0.34 |
| ▸ | MMP13 | P45452 | 4/20 | 0.34 |
| ▸ | MMP14 | P50281 | 4/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.34 |
| ▸ | MMP8 | P22894 | 3/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd1386 SCHEMBL4257077 | 0.90 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL4260128 | 0.88 | AR (0.52) | AKR1B1AKR1A1AR | |
| SCHEMBL4257016 | 0.88 | PTGDR2 (0.35) | AKR1B1AKR1A1 | |
| SCHEMBL4159776 | 0.87 | CNR1 (0.39) | AKR1B1AKR1A1PPARDADAMTS5 | |
| SCHEMBL4260042 | 0.86 | CNR1 (0.43) | AKR1B1AKR1A1 | |
| SCHEMBL23390595 | 0.84 | AKR1A1 (0.39) | AKR1B1AKR1A1 | |
| SCHEMBL4978488 | 0.82 | AR (0.41) | CHRM5CHRM3HSP90AA1ARP2RX3 | |
| SCHEMBL4167879 | 0.81 | AKR1A1 (0.35) | AKR1B1AKR1A1 | |
| SCHEMBL4254391 | 0.79 | MEN1 (0.46) | CHRM5AKR1B1AKR1A1MMP2MMP3 | |
| SCHEMBL4260823 | 0.79 | HSP90AA1 (0.52) | CHRM5HSP90AA1ADAMTS5SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | CHRM5 507/4885CHRM3 241/4885HSP90AA1 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.